- Home
- CRGX vs SVRA Comparison
CRGX vs SVRA Comparison
Compare CRGX & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- SVRA
- Stock Information
- Founded
- CRGX 2021
- SVRA N/A
- Country
- CRGX United States
- SVRA United States
- Employees
- CRGX N/A
- SVRA N/A
- Industry
- CRGX
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- CRGX
- SVRA Health Care
- Exchange
- CRGX Nasdaq
- SVRA Nasdaq
- Market Cap
- CRGX 621.4M
- SVRA 540.6M
- IPO Year
- CRGX 2023
- SVRA N/A
- Fundamental
- Price
- CRGX $12.39
- SVRA $2.93
- Analyst Decision
- CRGX Strong Buy
- SVRA Buy
- Analyst Count
- CRGX 6
- SVRA 7
- Target Price
- CRGX $31.80
- SVRA $9.86
- AVG Volume (30 Days)
- CRGX 287.3K
- SVRA 994.8K
- Earning Date
- CRGX 11-12-2024
- SVRA 03-06-2025
- Dividend Yield
- CRGX N/A
- SVRA N/A
- EPS Growth
- CRGX N/A
- SVRA N/A
- EPS
- CRGX N/A
- SVRA N/A
- Revenue
- CRGX N/A
- SVRA N/A
- Revenue This Year
- CRGX N/A
- SVRA N/A
- Revenue Next Year
- CRGX N/A
- SVRA N/A
- P/E Ratio
- CRGX N/A
- SVRA N/A
- Revenue Growth
- CRGX N/A
- SVRA N/A
- 52 Week Low
- CRGX $10.91
- SVRA $2.60
- 52 Week High
- CRGX $33.92
- SVRA $5.70
- Technical
- Relative Strength Index (RSI)
- CRGX 39.66
- SVRA 43.56
- Support Level
- CRGX $10.91
- SVRA $2.60
- Resistance Level
- CRGX $15.75
- SVRA $3.14
- Average True Range (ATR)
- CRGX 1.20
- SVRA 0.17
- MACD
- CRGX -0.11
- SVRA -0.00
- Stochastic Oscillator
- CRGX 30.08
- SVRA 47.83
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.